Gabriel Baertschi

DKSH is a leading Market Expansion Services provider with a focus on Asia, generating around 12 billion Swiss francs in annual revenue and supporting companies through distribution, marketing, and business development across 30 markets. • Member of the Nomination & Compensation Committee (NCC) and the Merger & Acquisition (MA) Subcommittee

Grünenthal is a privately owned, science-based global pharmaceutical company headquartered in Aachen, Germany, focused on pain management and related diseases. The company develops and commercializes innovative treatments addressing significant unmet medical needs, with a commercial presence across multiple regions worldwide. In FY2024, Grünenthal reported €1.8 billion in revenue and employs around 4,400 people globally. In recent years, the company has invested more than €2 billion in the acquisition of established brands, successfully integrating them to further strengthen its portfolio and international footprint. Grünenthal is guided by its vision of a “World Free of Pain”, combining innovation, strategic growth, and responsible business practices.

Managing an organization of over 3000 employes (including Operation, R&D, Commercial) and full accountability of P&L , sales >3bn USD. Moved from #12 to #8 in the Market

Member of the European, Middle East and African Senior Leadership Team, developing transformational strategy for a region of >10bn$ - main focus is on shaping new Organizational Design, Business Development, New Commercial Models and Market Access.

Japanese Pharmaceutical Manufacturers Association (JPMA). www.jpma.org.jp/

General Management Position. Accountability for P&L 1.5bilion $ and organisation of more than 1000 employees. Major achievements: *Delivered budget, share targets and addressed business shape issue in a industry leading way *Lead Transformation of the organization, in particular moving away from a traditional sales model towards a completely new sales model which lead to significant saving and competitive financial ratio (top quartile in the industry) *Developed & implemented New Commercial Models such as Inside Sales agent (telemarketing) and Service Team (new type of customer facing function) , Digital on large scale which allowed keeping S&MM ratio stable despite large drop in revenue. As a result generated additional profit and increased the customer facing contacts by +15% *Built a new organization with more cross-functionality ,set up along the product life cycle, addressing payers needs (new Real World Evidence /Value Demonstration Team) and integrating all the new commercial models for better customer experience and cost effective resource deployment * Implemented Impactful Leadership & OD initiatives, shaping the company culture, resulting in employee engagement increasing beyond Global high performing norms, improvement on 13 dimensions - this despite a downsizing of 20% of the workforce. +38 Talent progressing & Diversity improved. * Secured Access under the new Health Care Reform: Strong IQWIG benefit assessment for Brilique (ACS Therapy). Brilique is the first and only drug which has achieved this level of positive benefit assessment under the new health care reform * Accelerated launch performance of Brilique. After 14months of launch 37% of hospital discharged ACS patients in Germany receive Brilique (vs 33% for Effient and 29% for Plavix). This is the best performance in the world so far *Lead on behalf of the AstraZeneca Senior Leadership Team a multi -bilion $ business development project

Full P&L responsibility. Manage a growing organization with over 300 employees and over 120m$ sales. Mission to perform a turnaround within 24 months, ensuring AZ outperforms the market and maintain business shape despite significant loss of sales due to governmental intervention on key brands Crestor and Nexium. Reshape Management Team with strong commercial leaders that can step up as General Manager within 2 years. Raise the Sales & Marketing capability and reinforce believe and adherence to Governance. Major achievements: *Maintained 2009 business shape and profitability despite –substantial impact on top line due to unpredicted Governmental Intervention. This was achieved through targeted de-investment on non profitable brands and projects not aligned to strategy of key brands *Turned around product performance 6months after joining - delivering strong market share gains for key products through improved SFE productivity, Field Force Performance Management/Diagnosis and new Segmentation and Targeting approaches. AZ gained +2% market share for the first time in the last 36months *Successfully negotiated and locked the price with Ministery of Public Health (MoPH) for Crestor and Nexium for a 24months period with a minimum price erosion bringing predictability and reducing risk in the financial plan for the plan period. *Within 90 days reshaped the management team – managed out the current commercial and finance leader and recruited two strong S&M leaders (one ex Novartis GM and another ex Medtronic GM) and reinforced the middle marketing management layer through targeted strategic recruitments. *Successfully implemented a Compliance Improvement program

General Manager Position with responsibilities for four countries. Managing an organisation of more than 200 employee with P&L accountability of 30m USD. During Tenure moved AstraZeneca ranking from #8 to #4. Fastest growing multinational company among top 10 for four consecutive years. Built AZ Vietnam from 50 employees in 2005 to a highly competitive organisation of more than 200 employees in 2008. Attracting, developing and retaining the best talent achieved this. Create the N°1 sales, marketing & medical capability - with uncompromised ethics - resulting in constantly outperforming the market.

Ensure GI portfolio profit and sales maximised Globally with particular focus in strategic markets: EU, Japan, Mexico and Brazil through the optimisation of pricing, marketing and sales activities. . Provide commercial leadership of GI portfolio accounting for more than 2.2Bn$, by defining and delivering strategy and life cycle management plans to maximize Nexium Opportunity. Direct report: to International VP Sales & Marketing. Work cross functionally with Global Product Team (e.g.: Market Access, Pricing, Brand Team, Clinical Development) and Marketing Companies. • Exceed sales budget of Nexium at 105% in 2005 r (+29% vs. 04) and Exceeded contribution of Nexium by 27m$ (+37% vs. 04) • Exceed Nexium market share target. Better E.U. share penetration in 05 vs. 04 (+1.8 pt vs. +0.9pt) • Cross-functional leader for Target Product Profile and Claims for NEXIUM and AZD 0865 life cycle management input. This includes strong collaboration with key markets Regulatory, Medical and Payers • Identified major new business opportunities, which resulted into four new global life cycle initiatives and several local opportunities. • Delivered additional market share gains with the development & implementation of the Nexium Commercial Excellence Action Plan that included a full review of the Segmentation & Targeting, the development of a new sales campaign based on strong customer insight and a promotional mix optimisation based on detailed RoI analysis. Based on this program markets like Italy and France posted significant market share gains going from 3pts to 4pts volume market share gain within a year and Nexium exceed both sales and contribution targets in Europe. In Japan Losec doubled the growth in 12m.

Successfully launched the first Megabrand of AZ Switzerland. Despite very tight launch timelines succeeded to be ahead of all competitors (14% market share 4 months post-reimbursement). 2nd best ever Pharmaceutical launch in Switzerland.